Qingdao Conston Medical Technology Co.,ltd is a professional medical devices manufacture, that is committed to innovation, quality and excellence, our company aspires to consistently provide customers with the finest products, competitively priced and backed by world-class customer care. We continuously strive to be the best medical device manufacturing company to ensure our customers can rely on our products to ultimately improve the lives of the patients they serve.
The global surgical staplers market size is valued at USD 4.5 billion in 2024 and is expected to reach USD 8.7 billion by 2032, at a compound annual growth rate (CAGR) of 7.5% during the forecast period.The strong market growth is mainly driven by the increase in the number of surgeries worldwide and the advancement of surgical anastomosis techniques.
Vena Medical announced that its disposable vascular endoscope, MicroAngioscope, has been awarded the FDA "Breakthrough Device" designation. This is the first vascular endoscope to receive the FDA "Breakthrough Device" designation.
When we talk about staplers in China, the first thing that comes to mind is Johnson & Johnson and Medtronic. These two companies once occupied more than 90% of the stapler market in China. Now, with China's large-scale centralized procurement and the continuous emergence of high-quality domestic products, their market share is declining sharply. Chinese staplers have begun to take the initiative, and Johnson & Johnson and Medtronic may become Others in the future.
Recently, Olympus Corporation is about to undergo a comprehensive restructuring of its business operations. Company representative executive officer and former CEO Yasuo Takeuchi announced the changes during the release of fiscal 2025 third-quarter results. Takeuchi took over on an interim basis after Stefan Kaufmann pleaded guilty to drug charges in December. The reorganization is designed to improve the company's operational efficiency and further focus on patients and customers.
The global rigid endoscope market size was valued at USD 4.5 billion in 2024 and is expected to reach USD 7.3 billion by 2032, at a compound annual growth rate (CAGR) of 5.4% during the forecast period.This growth is driven by the continuous advancement of technology, the rising incidence of chronic diseases, and the growing demand for minimally invasive surgeries. These factors together drive the expansion of the global rigid endoscope market.